Model-Based Drug Development (MBDD) 101: A Primer on MBDD and Its Benefits

Drug Discovery and Development, Life Sciences, Pharmaceutical,
  • February 28, 2013 | 10am BST (UK) / 11am CEST (EU-Central) / 5am EDT (NA)
  • 0 min

Recording not available for this webinar

Developing new drugs is becoming an increasingly expensive and lengthy process. Making this process more efficient requires a new approach.

With model-based drug development (MBDD), mathematical models can be used early on to test extremely complex situations before deciding on a course of action. These models can identify the right dose, the right population, optimize clinical protocol, program, and portfolio designs, and compare candidates with existing drugs — ultimately providing better decisions and optimized returns.

Goals

In this webinar we will provide an overview of the basics of model based drug development and its practical applications in:

  • Selecting the right dose and population
  • Optimizing trial, program, and portfolio design
  • Quantitative decision making through computer modeling and simulation

We will present model based drug development principles, covering: concepts, methodologies, applications with case studies, benefits, and the overall impact on regulatory decisions.

Viewers will learn how model based drug development can help you to:

  • Improve communication across disciplines
  • Utilize the many data domains to improve drug development
  • Make better, quantitative, data-driven decisions

Speakers

N. Seth Berry, PharmD, Director, Clinical PK/PD and Modeling & Simulation, Quintiles Innovation

Dr. Berry is Director of Clinical Pharmacokinetic / Pharmacodynamic (PK/PD) Modeling and Simulation in the Quintiles Innovation Group. He has a PharmD from the University of Missouri-Kansas City, School of Pharmacy, a 2-year Post-Doctoral PK/PD Fellowship with the University of North Carolina, and a 2-year Pharmacometrics Fellowship with the Center for Drug Development Science, Georgetown University (now at the University of California – San Francisco).

Since joining Quintiles in 2004, Dr. Berry has focused on Model-Based Drug Development, with an emphasis in population PK/PD modeling and simulation. Dr. Berry has performed population PK/PD meta-analyses for regulatory submission labeling requirements and conducted clinical trial simulations for optimizing study design. Dr. Berry has numerous publications and presentations in the pharmacometrics discipline, while also mentoring PK/PD Fellows, providing workshops, and training seminars. Dr. Berry is a high performance computing expert with strong backgrounds in NONMEM®, S-Plus®, and R.

Russell Reeve, PhD, Senior Strategic Biostatistics Director, Quintiles

Dr. Reeve earned his B.S. in Mathematics from Utah State University, M.S. in Operations Research from Rensselaer Polytechnic Institute, and Ph.D. in Statistics from Virginia Polytechnic Institute and State University. Dr. Reeve has taught graduate statistics courses at University of Rochester and Memphis State University, and is currently an adjunct faculty in Analytics and North Carolina State University, and has previously been adjunct in Clinical Research at Campbell University.

Dr Reeve has broad industry experience. While at Syntex and Chiron, Dr. Reeve became involved in clinical modeling and simulation, designing a randomized concentration-controlled trial with Bayesian updating of the doses. While at Chiron, Dr. Reeve worked on a number of biologics agents and vaccines, such as interferon-a, vaccines for HCV, HPV, and influenza, as well as in vitro diagnostics based on ligand-binding and bDNA technologies. At Pharsight, Dr. Reeve was responsible for the scientific development of modeling and simulation software (WinNonlin, WinNonMix, and Trial Simulator), and managing the scientific advisory boards in these areas.

Dr. Reeve has since worked in the CRO industry, supporting more than 100 studies from Phase I through Phase IV. Dr. Reeve has published and has expertise in model-based drug development, including CATD and population modeling, has a patent in the field of metabolomics, and has been a leader in adaptive trial design and execution. He currently supports development of MBDD capabilities at Quintiles, is on the Quintiles Adaptive Trial Board, manages the Innovation MBDD Advisory Board, and consults with clients on development and trial design strategies.

Who Should Attend?

Life science executives with a background or interest in best practices for clinical development, clinical pharmacology, pharmacometrics, and/or biostatistics.

Relevant job functions include:

  • Biostatistician
  • Biometrics
  • Clinical Pharmacologist
  • Clinical Research (Scientist)
  • Clinical Director
  • Clinical Operations
  • Clinical Trial Associates
  • Clinical Project Manager / Director
  • Clinical Trial Manager
  • Pharmakokineticist
  • Pharmacometrician
  • Regulatory
  • Drug Safety
  • Medical Affairs and Strategy
  • Medical Director

Xtalks Partners

Quintiles

Quintiles is the only fully integrated bioPharmaceutical services company offering clinical, commercial, and consulting solutions worldwide. The Quintiles network of more than 27,000 engaged professionals in 59 countries works with an unwavering commitment to patients, safety and ethics. Quintiles helps bioPharmaceutical companies navigate risk and seize opportunities in an environment where change is constant. For more information, please visit www.quintiles.com/clinical-services/phase-i-iia/.

Media Partners

Related Webinars

Sign Up or Login To Register for this Webinar

Interested in this webinar? Sign up to register for any upcoming or recorded webinar or if you’re already a member Login.

Sign Up